Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PEG-ADM for acute respiratory distress syndrome
NL-OMON51280Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2022
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adrenomedullin pegol in acute respiratory distress syndrome (ARDS) (5 arms), sponsored by Bayer. Primary endpoint: Ventilator-free survival at Day 28. Started Mar 2022; status: active, not recruiting.
02
Drugs
adrenomedullin pegol
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NL-OMON51280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51280.